Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD

Summary

Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease surrogate markers of bone metabolism and early cardiovascular disease in individuals with moderate to severe airflow obstruction and a chronic bronchitis phenotype.

Timeline

Start

2013-02

Primary completion

2016-06

Completion

2016-06-30

Drugs

Indications